Beta Bionics, Inc.: financial analysis
Ratios worked out from 4 fiscal years of Beta Bionics, Inc.'s statements, compared with 1,209 companies in Healthcare.
Beta Bionics, Inc. scorecard#
Passes 3 of the 13 checks that could be worked out: strongest in financial health (2 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median3.3×Price to book 3.3× against Healthcare's median of 3.1×.
- ✗Price to sales below its peers' median7.5×Price to sales 7.5× against Healthcare's median of 3.7×.
- ✗Free cash flow yield above 5%-5.9%Free cash flow is -5.9% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- ✓Revenue grew in the newest year54.0%Revenue up 54.0% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.81 vs -8.60Diluted EPS -1.81 in fiscal 2025 against -8.60 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$73 MNet income -$73 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✗Operating margin above its peers' median-71.5%-71.5% against Healthcare's median of -7.7% (674 companies).
- ✗Return on equity above 15%-346.5%-346.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities8.7×Current ratio 8.66 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone12.82Z-score 12.82 (safe zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Net loss of $73 million, the 3th loss-making year in a row.
- Free cash flow was negative: -$56 million.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseyes
- Cash from operations exceeds profityes
- Long-term debt fell against assetsnot on file
- Current ratio roseyes
- No new shares issuedno
- Gross margin roseyes
- Asset turnover roseno
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.72 | × 1.2 | 0.87 |
| Retained earnings to assets | -1.13 | × 1.4 | -1.58 |
| Operating income to assets | -0.22 | × 3.3 | -0.72 |
| Market value to liabilities | 23.24 | × 0.6 | 13.94 |
| Revenue to assets | 0.30 | × 1 | 0.30 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|
| Gross margin | 55.4% | 55.1% | 52.6% | — | 58.4% | 44% | |
| Operating margin | -71.5% | -69.5% | -298.8% | — | -7.7% | 27% | |
| Net margin | -73.0% | -84.1% | -367.5% | — | -8.1% | 26% | |
| Return on equity | -346.5% | — | — | — | -36.9% | 3% | |
| Return on assets | -30.6% | -42.2% | -40.1% | — | -29.1% | 49% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|
| Revenue growth | 54.0% | 442.7% | — | — | 10.2% | 85% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|
| Current ratio | 8.66× | 6.28× | 9.78× | — | 3.18× | 82% | |
| Equity share of assets | 87.5% | -164.0% | -184.6% | — | 56.0% | 86% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|
| Free cash flow | $-56 M | $-52 M | $-33 M | — | $-11 M | 25% | |
| Free cash flow margin | -56.1% | -79.4% | -273.7% | — | -1.3% | 27% | |
| Capital spending share of revenue | 5.3% | 5.2% | 3.3% | — | 2.3% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|
| Asset turnover | 0.42× | 0.50× | 0.11× | — | 0.53× | 40% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).